The Docs Who Lift Podcast: Understanding Microdosing GLP-1 Agonists

Welcome back to the Docs Who Lift Podcast, where we simplify the complexities of a healthy lifestyle, exercise medicine, and weight loss. In this episode, Dr. Spencer Nadolsky and Dr. Carl dive into the concept of microdosing GLP-1 agonists and discuss the topline results from the recent KAGRA trial.

What Are GLP-1 Agonists?

GLP-1 (Glucagon-Like Peptide-1) agonists are a class of medications used to treat obesity and Type 2 diabetes. These drugs help regulate blood sugar levels, reduce appetite, and lead to significant weight loss. Notable GLP-1 agonists include Semaglutide (also known as Ozempic or Wegovy) and Liraglutide (Victoza or Saxenda).

Topline Results from the KAGRA Trial

The KAGRA trial aimed to investigate the efficacy of a new combination therapy involving Semaglutide and Krillin Tide, a novel amylin analog. While the full study details are yet to be published, the topline results indicate that the combination therapy resulted in a 23% reduction in body weight, which is impressive compared to the 12% weight loss seen with Krillin Tide alone.

Comparison of Weight Loss Outcomes

Combination therapy (Semaglutide + Krillin Tide): 23% weight loss
Krillin Tide alone: 12% weight loss
Semaglutide alone: 16% weight loss
Placebo group: 2.5% weight loss

Over 40% of participants in the combination group achieved 25% or greater weight loss, showcasing the potential of this new therapy.

The Concept of Microdosing

Microdosing refers to the practice of using sub-therapeutic doses of medication to minimize side effects while still achieving some therapeutic benefits. This concept has gained traction, particularly among those exploring the potential of GLP-1 agonists for weight management and metabolic health.

However, it is essential to approach microdosing with caution. While some patients may experience benefits from lower doses, the efficacy and safety of these regimens are not thoroughly studied. Dr. Nadolsky emphasizes that compounded versions of these medications lack the rigorous testing that FDA-approved formulations undergo.

Key Takeaways

GLP-1 agonists are effective for weight loss and blood sugar regulation.
The KAGRA trial shows promising results for a new combination therapy.
Microdosing may be beneficial for some individuals, but caution is advised.
Compounded versions of medications can pose risks due to lack of regulation and research.
Patients should consult healthcare professionals before considering microdosing or alternative therapies.

Conclusion

As new therapies emerge, understanding their mechanisms and potential benefits is crucial. The KAGRA trial results highlight the promise of combination therapies in the GLP-1 space. However, it is vital to approach microdosing with caution and to prioritize well-studied, FDA-approved medications for therapeutic use.

For more insights and updates on health and wellness, tune in to the Docs Who Lift Podcast!